US 2019/0062330 A1 · KRAS G12C INHIBITORS

Kras g12c inhibitors

AssigneesMirati Therapeutics, Inc., Array BioPharma Inc.

InventorsJames F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Jay Bradford Fell, John P. Fischer, John J. Gaudino, Erik James Hicken, Ronald Jay Hinklin, Matthew Randolf Lee, Matthew Arnold Marx, Macedonio J. Mejia, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Henry J. Zecca

Life of this patent

Estimating the term…

Abstract

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

Claims5

Dependent claims

A method for treating a cancer comprising administering to a patient having a cancer a therapeutically effective amount of a compound selected from the group consisting of

and pharmaceutically acceptable salts thereof.

Dependencies are inferred from the claim text.

Facts

Application

16/173,726Filed 29 Oct 2018

Priority

18 May 2016

Published

28 Feb 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification7 codes

C07D 471/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61P 35/00
Antineoplastic agents
A61P 35/02
Antineoplastic agents: specific for leukemia
A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00

Family

Application62/338,116Us provisional application · filed 18 May 2016

Application62/444,614Us provisional application · filed 10 Jan 2017

Application15/814,279Continuation · filed 15 Nov 2017

Application16/173,726Continuation

Application15/814,279Continuation in part

US 10,125,134 B2Related patent

US 10,633,381 B2Related patent

US 2018/0072723 A1Published application

US 2019/0062330 A1This patent

From the US filing history. Foreign family members aren’t listed.